Fig. 2

Per-sample OncoPrint of genomic alterations and cancer-derived 5-mC signals. Plasma samples with 5-mC scores exceeding the maximum value in the healthy donor cohort (0.6870) were considered tumor DNA-positive. Positivity for copy number alterations was evaluated similarly (t-MAD score ≥ 0.0081). Mutations, fusions, and focal amplifications with a relative abundance or variant allele frequency ≥ 0.01% were deemed tumor DNA-positive. Percent of tumor DNA-positive samples per biomarker are indicated on the right. ALK, anaplastic lymphoma kinase; BRAF, B-raf proto-oncogene; EGFR, epidermal growth factor receptor; ERBB2, Erb-B2 receptor tyrosine kinase 2; KRAS, v-Kir-Ras2 Kirsten rat sarcoma viral oncogene homolog; MET, MET proto-oncogene; TP53, tumor protein 53; t-MAD, trimmed median absolute deviation from copy number neutrality